Sanofi to review its new eczema drug amlitelimab - Meet them in May

Corvus shares nearly triple on positive data for eczema pill

An immune drug developer raises $50M to finance its eczema drug testing

Nektar sees silver lining as autoimmune drug ‘narrowly’ misses in alopecia study - Meet them in May

J&J eyes $100B in sales amid gains for cancer, immune drugs - Meet them in May

Alumis soars as TYK2 drug hits mark in psoriasis trials - Meet them in May

Galapagos TYK2 drug hits goal in one trial, misses in another

Takeda says $4B TYK2 drug succeeds in large psoriasis studies

Pfizer-backed Priovant scores again with fast-rising brepocitinib in midstage study

Connect’s Dupixent challenger hits the mark in phase 3 eczema trial

Apogee strengthens case for longer-lasting eczema drug

Anthony Melione

Vice President Imaging Endpoints Canfield Scientific

Wednesday 20th May 2026

Efficacy Endpoints with Validated Imaging Tools

4:00 pm

High quality, reproducible imaging builds confidence for quality oversight and quantitative measurements for regulatory endpoints submission
Objective, standardized assessments to support efficacy claims
Leveraging large dermatology data and AI for systemic impact
Imaging focused Clinical Outcome Assessments via secure, compliant systems